Header Ads Widget

Responsive Advertisement

AstraZeneca: A Successful Corona Vaccine

 AstraZeneca: A Successful Corona Vaccine

London: The CEO of AstraZeneca, a British Swedish pharmaceutical company, confirmed that the vaccine his company developed in cooperation with the University of Oxford had successfully achieved a "success equation" in terms of efficacy against Covid-19.

In an interview with The Sunday Times, Pascal Soriot said that the "Oxford AstraZeneca" vaccine is currently undergoing evaluation by the UK Independent Medicines Regulatory Agency and can provide "100% protection" for acute COVID-19 cases requiring hospitalization.

AstraZeneca: A Successful Corona Vaccine

He expressed his belief that the experience would prove that his organization had developed a vaccine with efficacy equivalent to 95% and 94.5% of "Pfizer-Biantai" and "Modena" respectively.

He said: "We believe that we have concluded the success formula and how to achieve effective results after two doses," noting that these data will be released at some point.

On December 23, the British government announced that the developer of the "Oxford AstraZeneca" vaccine had submitted its data to the Medicines and Healthcare products Regulatory Agency.

According to the "Sunday Telegraph", the authorities are expected to approve the distribution of the vaccine on Monday. The "Pfizer Bionic" vaccine is the first to be licensed for use by a British institution in the United Kingdom, and since last month it has been administered to 600,000 groups of the most vulnerable groups in the country .

Initial trials showed mixed results for the AstraZeneca vaccine. Initially, the average effective rate was 70% and then increased to 90% depending on the dose.

In large-scale trials conducted in the United Kingdom and Brazil, the average vaccination rate exceeded the average level, and for those who took two doses of the vaccine, the effective rate was 62%.

For volunteers who took half the dose initially and then took a dose a month later, the efficacy was 90%.

Suryut said he was surprised by the initial results and added, "We want a simpler result." There is widespread criticism of the lack of clarity and transparency about the difference in results. Soriot said he did not expect the subsequent rejection.

The vaccine is based on a version taken from chimpanzees

The, vaccine, is, based ,on ,a, version ,taken, from ,chimpanzees

He added, "We thought people would be a little disappointed, that's for sure, but we didn't expect this storm."

People are pinning high hopes on the AstraZeneca vaccine, which is based on inexpensive chimpanzee virus and is weaker.

The AstraZeneca vaccine also has logistical advantages, because it can be stored and transported under normal cooling conditions of 2 to 8 ° C for at least six months, which is incomparable with the "Pfizer Bionic" vaccine, which should be at minus 70 degrees. Under storage.

The AstraZeneca vaccine is expected to have gathered the specifications required for approval by the British authorities.

The British government has requested 100 million doses and will provide 40 million doses by the end of March. British officials hope the vaccine will end the spread of the virus in the United Kingdom, which is one of the worst-hit countries, with nearly 70,000 deaths.

In the past week, infections have increased across the country, especially in the southeast of the United Kingdom, and it is believed that this virus has become more contagious after it became more widespread and was first detected in the United Kingdom.

According to a British study, this new mutated virus is 50% to 74% contagious. In order to curb the spread of the disease, millions of people across the UK have come under tighter lockdown restrictions that came into effect on December 26th.

Dozens of countries have imposed travel restrictions on the UK to prevent the second wave from spreading.

Finance Minister Ritchie Sunak admitted in an article in the Sunday Mail that this year has been a tough year for everyone in this country.

But he added, "The early distribution of vaccines and the excellent work of our scientists and the National Health Administration mean we can now see the light at the end of the tunnel."

The British pharmaceutical manufacturer said it will produce about 200 million doses of AstraZeneca vaccine by the end of this year, and more than 700 million doses will be produced globally by the end of March next year.

Read also :

Post a Comment